Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
221-240 of 331 trials

Recurrent Grade-4 Glioma: Bortezomib and Temozolomide Study

We are studying the safety and effectiveness of combining Bortezomib with Temozolomide for patients with recurrent grade-4 glioma. This research may help improve treatment options for this challenging condition.

Malignant Glioma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Chronic Cluster Headache: Botulinum Toxin Treatment Study

We are investigating whether botulinum toxin can help people with chronic cluster headaches that haven't responded to other treatments. The study will also look at safety and how it affects headache frequency and quality of life.

Chronic Cluster Headache3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteNeurology

Pancreatic Cancer: GEMBRAX and FOLFIRINOX Treatment Study

We are exploring a new treatment sequence for patients with locally advanced pancreatic cancer to see if it improves outcomes and tolerability. This study will help us understand its effects on survival and quality of life.

Non-resectable Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Hypertrophic Cardiomyopathy: Bisoprolol vs. Verapamil

We are studying the effects of Bisoprolol and Verapamil on symptoms and heart function in patients with non-obstructive hypertrophic cardiomyopathy. Our goal is to see if these treatments can improve exercise capacity and reduce heart rhythm issues.

Non-obstructive Hypertrophic Cardiomyopathy3-6 monthsMonitoring phase (IV)Standard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

ADHD and Depression: Dexamfetamine Formulations Study

We are investigating the safety and effectiveness of two dexamfetamine sulfate formulations for adults with ADHD and moderate to severe depression. This study aims to see how these treatments compare to a placebo in improving symptoms and managing side effects.

Major DepressionAttention Deficit Hyperactivity Disorder (ADHD)3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPsychiatry

Osteogenesis Imperfecta: Losartan Therapy Study

We are investigating the right dose of losartan for older adolescents and adults with Osteogenesis Imperfecta. The study aims to see how it affects bone health and quality of life.

Brittle Bone Disease3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Actinic Keratosis: Keramod Gel vs. Aldara Cream

We are studying whether Keramod Gel works better than Aldara Cream for treating actinic keratosis in adults. The trial will also assess safety and how well patients tolerate each treatment.

Actinic Keratosis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesDermatology

Metastatic Tumors: Atezolizumab with SABR

We are studying the effects of a new combination treatment of atezolizumab and radiotherapy for patients with metastatic tumors. This trial aims to see if this approach can help improve survival rates and understand its safety.

Metastatic Tumors3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Functional Dyspepsia: Rikkunshito Study

We are investigating whether Rikkunshito can help relieve symptoms in patients with functional dyspepsia. The study also looks at how it may affect the digestive lining and overall gut function.

Functional Dyspepsia3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Alcohol-Associated Hepatitis: Alpha-1 Antitrypsin Treatment

We are studying whether intravenous Alpha-1 Antitrypsin can reduce inflammation in patients with severe alcohol-associated hepatitis. The trial also looks at its safety and effects on liver health.

Alcohol-Associated Hepatitis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Alpha-1 Antitrypsin Deficiency: Prolastin® Self-Infusion Therapy

We are studying the safety of a self-infusion therapy with Prolastin® for patients with severe alpha-1-antitrypsin deficiency. The trial also looks at quality of life and patient satisfaction with this treatment.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Posttraumatic Headache: Botulinum Toxin A Study

We are investigating whether botulinum toxin A can safely reduce the number of headache days for individuals with posttraumatic headaches. The study also looks at biological markers to see if they can predict treatment success.

Post-Traumatic Headache3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Primary Biliary Cholangitis: Golexanolone Study

We are testing a new medication, golexanolone, for individuals with primary biliary cholangitis who have significant fatigue and cognitive difficulties. The study aims to evaluate its safety and effects on daily life and cognitive function.

Primary Biliary Cholangitis3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesHepatologyInternal Medicine

Drug-Resistant Epilepsy: Rapamycin Study

We are investigating whether rapamycin is safe and effective for people with drug-resistant epilepsy due to tuberous sclerosis complex. The study also examines its effects on related neuropsychiatric disorders and tumors.

Tuberous Sclerosis Complex3-6 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNeurology

Myelofibrosis: Study of Pacritinib vs. Standard Treatment

We are investigating whether pacritinib can better reduce spleen size and improve symptoms in patients with myelofibrosis. This trial is for those with severe low platelet counts and compares pacritinib to physician's choice of therapy.

Post-Polycythaemia Vera MyelofibrosisPrimary MyelofibrosisPost-Essential Thrombocythaemia Myelofibrosis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Crohn's Disease: Adalimumab Treatment Study

We are comparing a new approach using adalimumab for newly diagnosed Crohn's disease patients against standard treatments. The goal is to see which method is safer and more effective in the long run.

Crohn's Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Ewing Sarcoma: Comparing Chemotherapy Treatments

We are studying different chemotherapy regimens for patients with recurrent or refractory Ewing Sarcoma. Our goal is to find the most effective and patient-friendly treatment option.

Ewing's Sarcoma3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: Venetoclax vs. Intensive Chemotherapy

We are studying whether venetoclax with low-dose cytarabine can improve outcomes for patients with favorable risk acute myeloid leukemia compared to intensive chemotherapy. This trial will help us understand the best treatment options for this condition.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Liver Transplant: QEL-001 Treatment Study

We are testing a new CAR T cell therapy for patients who received an HLA-A2 mismatched liver transplant. The goal is to evaluate its safety and how well it works in this specific group.

Liver Transplant Rejection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

Hereditary Angioedema: Deucrictibant Tablet Study

We are evaluating a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The study aims to determine its effectiveness and safety compared to a placebo.

Hereditary Angioedema3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine